Trial · NCT00560352
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) and Recommended MTD of Dasatinib in Combination With Bortezomib and Dexamethasone | All Treated | MTD dasatinib | NA | mg QD | |
| Maximum Tolerated Dose (MTD) and Recommended MTD of Dasatinib in Combination With Bortezomib and Dexamethasone | All Treated | Recommended MTD dasatinib | 140 | mg QD | |
| Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry | Dasatinib, 50 mg BID | Complete response (CR) | 0 | Percentage of participants | |
| Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry | Dasatinib, 100 mg QD | Complete response (CR) | 0 | Percentage of participants | |
| Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry | Dasatinib, 140 mg QD | Complete response (CR) | 0 | Percentage of participants | |
| Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry | Dasatinib, 50 mg BID | Very good partial response (VGPR) | 0 | Percentage of participants | |
| Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry | Dasatinib, 100 mg QD | Very good partial response (VGPR) | 0 | Percentage of participants | |
| Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry | Dasatinib, 140 mg QD | Very good partial response (VGPR) | 0 | Percentage of participants | |
| Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry | Dasatinib, 50 mg BID | Partial response (PR) | 14.3 | Percentage of participants | |
| Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry | Dasatinib, 100 mg QD | Partial response (PR) | 0 | Percentage of participants | |
| Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry | Dasatinib, 140 mg QD | Partial response (PR) | 0 | Percentage of participants | |
| Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry | Dasatinib, 50 mg BID | Minimal response (MR) | 0 | Percentage of participants | |
| Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry | Dasatinib, 100 mg QD | Minimal response (MR) | 0 | Percentage of participants | |
| Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry | Dasatinib, 140 mg QD | Minimal response (MR) | 25 | Percentage of participants | |
| Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry | Dasatinib, 50 mg BID | Stable disease (SD) | 57.1 | Percentage of participants | |
| Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry | Dasatinib, 100 mg QD | Stable disease (SD) | 0 | Percentage of participants | |
| Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry | Dasatinib, 140 mg QD | Stable disease (SD) | 0 | Percentage of participants | |
| Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry | Dasatinib, 50 mg BID | Progressive disease (PD) | 14.3 | Percentage of participants | |
| Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry | Dasatinib, 100 mg QD | Progressive disease (PD) | 33.3 | Percentage of participants | |
| Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry | Dasatinib, 140 mg QD | Progressive disease (PD) | 0 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00560352/results